Scarica l'app Stockscreener
39.65
2.03%
0.79
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$38.86
Aprire:
$38.74
Volume 24 ore:
5.11M
Relative Volume:
1.46
Capitalizzazione di mercato:
$16.94B
Reddito:
$2.31B
Utile/perdita netta:
$1.66B
Rapporto P/E:
17.26
EPS:
2.297
Flusso di cassa netto:
$827.02M
1 W Prestazione:
+1.46%
1M Prestazione:
-0.20%
6M Prestazione:
+9.02%
1 anno Prestazione:
+53.44%
Intervallo 1D:
$38.51
$39.87
Intervallo di 1 settimana:
$38.29
$39.87
Portata 52W:
$25.40
$41.24
Royalty Pharma Plc Stock (RPRX) Company Profile
Nome
Royalty Pharma Plc
Settore
Industria
Telefono
(212) 883-0200
Indirizzo
110 EAST 59TH STREET, NEW YORK, NY
Confronta RPRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
39.65 | 16.60B | 2.31B | 1.66B | 827.02M | 2.297 |
|
VRTX
Vertex Pharmaceuticals Inc
|
448.80 | 114.71B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
763.23 | 81.59B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.83 | 52.87B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
800.88 | 51.72B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.20 | 37.77B | 447.02M | -1.18B | -906.14M | -6.1812 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-30 | Iniziato | Goldman | Buy |
| 2025-05-16 | Iniziato | Morgan Stanley | Overweight |
| 2024-06-03 | Downgrade | UBS | Buy → Neutral |
| 2022-06-14 | Ripresa | UBS | Buy |
| 2022-05-13 | Iniziato | Scotiabank | Sector Outperform |
| 2022-04-27 | Iniziato | Goldman | Buy |
| 2022-04-14 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-04-06 | Ripresa | Morgan Stanley | Overweight |
| 2021-10-29 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-07-30 | Iniziato | Tigress Financial | Buy |
| 2020-11-09 | Aggiornamento | UBS | Neutral → Buy |
| 2020-07-14 | Iniziato | Evercore ISI | In-line |
| 2020-07-13 | Iniziato | BofA Securities | Buy |
| 2020-07-13 | Iniziato | Citigroup | Neutral |
| 2020-07-13 | Iniziato | Cowen | Outperform |
| 2020-07-13 | Iniziato | Goldman | Neutral |
| 2020-07-13 | Iniziato | JP Morgan | Neutral |
| 2020-07-13 | Iniziato | Morgan Stanley | Equal-Weight |
| 2020-07-13 | Iniziato | SunTrust | Buy |
| 2020-07-13 | Iniziato | UBS | Neutral |
Mostra tutto
Royalty Pharma Plc Borsa (RPRX) Ultime notizie
Financiere des Professionnels Fonds d investissement inc. Invests $933,000 in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma Acquires Remaining Royalty Interest in Roche’s Evrysdi for $240 Million and Potential Milestones - citybiz
Why (RPRX) Price Action Is Critical for Tactical Trading - Stock Traders Daily
What's Going On With Royalty Pharma Stock Wednesday?Royalty Pharma (NASDAQ:RPRX) - Benzinga
Royalty Pharma buys remaining royalty interest in Roche drug Evrysdi - MSN
Royalty Pharma Acquires Remaining Evrysdi Royalties From PTC Therapeutics - Nasdaq
Royalty Pharma acquires final portion of Evrysdi royalty for $240 million By Investing.com - Investing.com Nigeria
PTC Therapeutics IncCo, Royalty Pharma Inv - 富途牛牛
Royalty Pharma acquires remaining royalty interest in Roche's Evrysdi for $240 million - marketscreener.com
Royalty Pharma Buys Remaining Royalty Interest in Roche's Evrysdi - marketscreener.com
Royalty Pharma acquires final portion of Evrysdi royalty for $240 million - Investing.com
Royalty Pharma (NASDAQ:RPRX) EVP Sells $786,400.00 in Stock - MarketBeat
Royalty Pharma stock rises after acquiring full Evrysdi royalty By Investing.com - Investing.com Canada
Royalty Pharma stock rises after acquiring full Evrysdi royalty - Investing.com India
Royalty Pharma Acquires Final Portion of Evrysdi Royalty from PTC Therapeutics for $240 Million - Quiver Quantitative
Royalty Pharma acquires remaining Evrysdi royalty for $240 million - StreetInsider
Nuvalent’s royalty interest acquired by Royalty Pharma - MSN
Royalty Pharma PLC $RPRX Shares Sold by Marathon Asset Management Ltd - MarketBeat
Royalty Pharma announces planned legal leadership transition - MSN
Royalty Pharma Plc's (NASDAQ:RPRX) Earnings Haven't Escaped The Attention Of Investors - 富途牛牛
World Investment Advisors Takes $1.70 Million Position in Royalty Pharma PLC $RPRX - MarketBeat
Can Royalty Pharma plc (RPD) stock ride next bull market cycleReal Estate Investment Trusts & Capitalize On Fast Trends - bollywoodhelpline.com
Royalty Pharma PLC $RPRX Stock Holdings Lifted by Voya Investment Management LLC - MarketBeat
Swedbank AB Acquires 42,800 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Friedenthal Financial Acquires Shares of 29,322 Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma (RPRX): Reassessing Valuation After MYQORZO’s FDA Approval Unlocks New Royalty Cash Flows - Sahm
Royalty Pharma (NASDAQ:RPRX) EVP Sells $767,600.00 in Stock - MarketBeat
Royalty Pharma Announces Planned Legal Leadership Transition - TipRanks
Royalty Pharma names McGivern as chief legal officer - StreetInsider
Royalty Pharma plc Announces Executive Changes - marketscreener.com
The Technical Signals Behind (RPRX) That Institutions Follow - Stock Traders Daily
Royalty Pharma Gains from MYQORZO FDA Approval - TradingView — Track All Markets
Royalty Pharma (NASDAQ:RPRX) EVP Sells $3,060,375.22 in Stock - MarketBeat
Insider Selling: Royalty Pharma (NASDAQ:RPRX) EVP Sells 30,654 Shares of Stock - MarketBeat
Royalty Pharma : Q4 2025 Pre-Quarterly Results Communication - marketscreener.com
How risky is Royalty Pharma plc (RPD) stock compared to peersPortfolio Update Summary & AI Powered Buy and Sell Recommendations - ulpravda.ru
Royalty Pharma PLC $RPRX Shares Sold by Thrivent Financial for Lutherans - MarketBeat
Dividend Watch: How Royalty Pharma plc stock compares to growth peers - Улправда
Insider Selling: Royalty Pharma (NASDAQ:RPRX) CFO Sells 69,582 Shares of Stock - MarketBeat
Royalty Pharma (NASDAQ:RPRX) EVP Marshall Urist Sells 20,000 Shares - MarketBeat
Royalty Pharma Insider Sold Shares Worth $766,420, According to a Recent SEC Filing - marketscreener.com
VP Urist Sells 20,000 ($766.4K) Of Royalty Pharma PLC [RPRX] - TradingView — Track All Markets
[Form 4] Royalty Pharma plc Insider Trading Activity - Stock Titan
UBS reiterates Buy rating on Nuvalent stock, citing Royalty Pharma deal - Investing.com Nigeria
Royalty Pharma buys royalty interest in Nuvalent cancer drugs for up to $315 mln - MSN
Royalty Pharma PLC (NASDAQ:RPRX) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Nuvalent’s Royalty Interest Acquired by Royalty Pharma - The Globe and Mail
Shareholder Sandy Lamm LLC Files To Sell 160,000 Of Royalty Pharma PLC [RPRX] - TradingView — Track All Markets
How Investors Are Reacting To Royalty Pharma (RPRX) Expanding Oncology Royalties With Nuvalent Deal - Sahm
Royalty Pharma shares edge higher on acquisition of oncology drug royalties - MSN
Royalty Pharma Plc Azioni (RPRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.06%
0.36%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):